Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 274


Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.

Sehl ME, M Gruber T, McWilliams JP, Marder VJ.

Am J Hematol. 2015 Jun;90(6):561-3. doi: 10.1002/ajh.23969. No abstract available.


Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.

Bizjak N, Bajd F, Vidmar J, Blinc A, Perme MP, Marder VJ, Novokhatny V, Serša I.

Thromb Res. 2014 May;133(5):908-13. doi: 10.1016/j.thromres.2014.02.008.


Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family.

Kim B, Hing ZA, Wu A, Schiller T, Struble EB, Liuwantara D, Kempert PH, Broxham EJ, Edwards NC, Marder VJ, Simhadri VL, Sauna ZE, Howard TE, Kimchi-Sarfaty C.

Br J Haematol. 2014 Apr;165(1):154-8. doi: 10.1111/bjh.12713. No abstract available.


Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.

Bizjak N, Bajd F, Vidmar J, Blinc A, Marder VJ, Novokhatny V, Serša I.

Blood Coagul Fibrinolysis. 2013 Oct;24(7):711-4. doi: 10.1097/MBC.0b013e328361bd48.


Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C.

Thromb Haemost. 2012 Nov;108(5):903-12. doi: 10.1160/TH12-07-0482.


Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.


Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.

Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Novokhatny V, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2012 May 16;4(1):10.


Interference of thrombin in immunological assays for hirudin specific antibodies.

Hamilton RG, Levy JH, Marder VJ, Sane DC.

J Immunol Methods. 2012 Jul 31;381(1-2):50-8. doi: 10.1016/j.jim.2012.04.008.


Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.

Marder VJ, Comerota AJ, Shlansky-Goldberg RD, Davis JP, Deng C, Hanna K, Fineberg D.

J Thromb Haemost. 2012 Jun;10(6):985-91. doi: 10.1111/j.1538-7836.2012.04728.x.


Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH).

Cao L, Wallace WD, Eshaghian S, Linhares Y, Marder VJ.

Int J Hematol. 2011 Nov;94(5):483-7. doi: 10.1007/s12185-011-0936-2.


Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model.

Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2011 Sep 20;3(1):10. doi: 10.1186/2040-7378-3-10.


Ancrod and fibrin formation: perspectives on mechanisms of action.

Liu S, Marder VJ, Levy DE, Wang SJ, Yang F, Paganini-Hill A, Fisher MJ.

Stroke. 2011 Nov;42(11):3277-80. doi: 10.1161/STROKEAHA.111.622753.


Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.

Marder VJ.

J Thromb Haemost. 2011 Jul;9 Suppl 1:364-73. doi: 10.1111/j.1538-7836.2011.04370.x. Review.


Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.

Marder VJ, Blinc A, Gruber T, Tratar G, Sabovic M, Starkman S, Jahan R, Duckwiler G, Vinuela F, Tateshima S, Liebeskind D, Ovbiagele B, Ali L, Kim D, Gonzalez N, Vespa PM, Saver JL.

Stroke. 2011 Aug;42(8):2222-8. doi: 10.1161/STROKEAHA.110.609198.


CT and MRI early vessel signs reflect clot composition in acute stroke.

Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Viñuela F, Salamon N, Villablanca JP, Vinters HV, Marder VJ, Saver JL.

Stroke. 2011 May;42(5):1237-43. doi: 10.1161/STROKEAHA.110.605576.


Thrombolysis with plasmin: implications for stroke treatment.

Marder VJ, Jahan R, Gruber T, Goyal A, Arora V.

Stroke. 2010 Oct;41(10 Suppl):S45-9. doi: 10.1161/STROKEAHA.110.595157.


Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.

Marder VJ, Manyak S, Gruber T, Goyal A, Moreno G, Hunt J, Bromirski J, Scuderi P, Petteway SR Jr, Novokhatny V.

Thromb Haemost. 2010 Oct;104(4):780-7. doi: 10.1160/TH09-10-0742.


Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.

Warkentin TE, Cook RJ, Marder VJ, Greinacher A.

J Thromb Haemost. 2010 Mar;8(3):504-12. doi: 10.1111/j.1538-7836.2009.03735.x.


Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.

Marder VJ, Novokhatny V.

J Thromb Haemost. 2010 Mar;8(3):433-44. doi: 10.1111/j.1538-7836.2009.03701.x. Review.


Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.

Marder VJ.

Thromb Res. 2009;123 Suppl 4:S56-61. doi: 10.1016/S0049-3848(09)70145-8. Review.

Items per page

Supplemental Content

Loading ...
Support Center